Hims & Hers Health (HIMS)
(Real Time Quote from BATS)
$15.78 USD
-0.26 (-1.62%)
Updated Aug 8, 2024 03:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HIMS 15.78 -0.26(-1.62%)
Will HIMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HIMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HIMS
Eli Lilly: The Next $1 Trillion Market Cap Stock?
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
HIMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
Boston Scientific (BSX) Rides on Global Growth, Buyouts
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
Other News for HIMS
Hold Rating on Hims & Hers Health Amid Mixed Financial Signals
Hold Rating on Hims & Hers Health Amid Revenue Uptick and Market Uncertainties
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Hold Rating on Hims & Hers Health Amidst Revenue Growth and Strategic Expansion Uncertainties
Palantir, Uber report Q2 beats: Morning Buzz